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Abstract
Background: Deep inspiration breath hold (DIBH) reduces heart and left anterior descending artery (LAD) dose during
left-sided breast radiation therapy (RT); however there is limited information about which patients derive the most
benefit from DIBH. The primary objective of this study was to determine which patients benefit the most from DIBH by
comparing percent reduction in mean cardiac dose conferred by DIBH for patients treated with whole breast RT ± boost
(WBRT) versus those receiving breast/chest wall plus regional nodal irradiation, including internal mammary chain (IMC)
nodes (B/CWRT + RNI) using a modified wide tangent technique. A secondary objective was to determine if DIBH was
required to meet a proposed heart dose constraint of Dmean < 4 Gy in these two cohorts.
Methods: Twenty consecutive patients underwent CT simulation both free breathing (FB) and DIBH. Patients were
grouped into two cohorts: WBRT (n = 11) and B/CWRT + RNI (n = 9). 3D-conformal plans were developed and FB was
compared to DIBH for each cohort using Wilcoxon signed-rank tests for continuous variables and McNemar’s test for
discrete variables. The percent relative reduction conferred by DIBH in mean heart and LAD dose, as well as lung V20
were compared between the two cohorts using Wilcox rank-sum testing. The significance level was set at 0.05 with
Bonferroni correction for multiple testing.
Results: All patients had comparable target coverage on DIBH and FB. DIBH statistically significantly reduced mean
heart and LAD dose for both cohorts. Percent reduction in mean heart and LAD dose with DIBH was significantly
larger in the B/CWRT + RNI cohort compared to WBRT group (relative reduction in mean heart and LAD dose: 55.9 %
and 72.1 % versus 29.2 % and 43.5 %, p < 0.02). All patients in the WBRT group and five patients (56 %) in the B/
CWBRT + RNI group met heart Dmean <4 Gy with FB. All patients met this constraint with DIBH.
Conclusions: All patients receiving WBRT met Dmean Heart < 4 Gy on FB, while only slightly over half of patients
receiving B/CWRT + RNI were able to meet this constraint in FB. DIBH allowed a greater reduction in mean heart and LAD
dose in patients receiving B/CWRT + RNI, including IMC nodes than patients receiving WBRT. These findings suggest
greatest benefit from DIBH treatment for patients receiving regional nodal irradiation.
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Background
Adjuvant radiation therapy (RT) for breast cancer patients
reduces the risk of local recurrence and improves overall
survival [1, 2]. RT to the left breast and chest wall results
in non-negligible dose to the heart and coronary arteries.
Several large studies have demonstrated increased cardiac
mortality associated with RT for left-sided breast cancer
[3–5]. The use of cardiotoxic chemotherapy may further
increase this risk [6].
Techniques to minimize irradiation of cardiac structures
without compromise to target coverage have been devel-
oped including the use of deep inspiration breath hold
(DIBH). While there is not yet any clinical evidence show-
ing reduced cardiac toxicity or morbidity when using
DIBH, numerous planning studies have demonstrated
decreased dose to cardiac structures when compared to
FB [7–15]. However, threshold doses to the heart and cor-
onary arteries have not been determined [13]. A recent
international breast cancer randomized trial (NSABP B-
51/RTOG1304), has proposed that the mean heart dose
(Dmean Heart) should be <4 Gy during left-sided breast/
chest wall irradiation [16]. Dose limits have not been
established for the left-anterior descending coronary artery
(LAD), which may be the crucial target to mitigate ische-
mic heart disease risk from RT [17, 18].
DIBH is not uniformly implemented. A survey con-
ducted by the authors in May 2014 identified that only
four of fourteen cancer centers in Western Canada were
using DIBH during RT for left-sided breast cancer, in part
because of concerns about technical complexity and infra-
structure constraints. Our institution implemented a visu-
ally monitored DIBH technique in June 2013 to avoid
challenges with limited access to respiratory gating devices
on older linear accelerators and to reduce simulation and
treatment delivery time for DIBH.
The primary objective of this study was to identify which
patients would benefit most from DIBH by determining
whether a difference in percent mean cardiac dose reduc-
tion exists in patients receiving whole breast radiotherapy
alone compared to those also receiving regional nodal ir-
radiation (RNI), including internal mammary chain (IMC)
nodal RT using a modified wide tangent technique. Our
secondary objective was to determine if DIBH was required
to meet the proposed mean heart dose constraint of <4 Gy.
Methods
Patient population
Twenty consecutive patients with left-sided breast cancer
treated at our center starting in June 2013 were included if
they were able to maintain DIBH ≥ 20 seconds. All pa-
tients received CT simulation with standard FB and DIBH
and were treated on a wing-board. The DIBH technique
involved training patients immediately prior to CT simula-
tion. The distances from table-top to the mid-axillary line
in FB and DIBH were recorded and displacements were
calculated. Once reproducibility in DIBH was established
based on these measurements, patients were translated
through the CT with bellows (Philips, The Netherlands) to
ensure stability of breath hold.
Clinical target volumes (CTV) included the breast or
chest wall (CTVb) for all patients. If the regional nodes
were to be treated, additional CTVs for the internal mam-
mary chain nodes inclusive of the first to third interspaces
(CTVIMC) and axillary plus supraclavicular nodes were de-
lineated. CTVb was based on RTOG guidelines [19]. IMC
nodes were delineated by a 1 cm diameter circle around
the internal mammary vessels from the first to third inter-
costal space, and cropped from lung and bone [20]. If
boost to the seroma was deemed necessary, PTVboost was
delineated by expanding the seroma contour by 1 cm in
all directions. Organs at risk (OAR) were defined as the
heart, LAD, and left lung. The heart and LAD were con-
toured based on previously published guidelines [21].
Treatment planning
For each patient, 3D-CRT plans on the FB and DIBH
scans were developed using forward planning, field-based
techniques. Tangential medio-lateral opposed fields with
dynamic wedges were used to cover the CTVb ± CTVIMC.
IMC nodes were covered using a modified wide tangent
technique [20] where tangent fields were widened to in-
clude the CTVIMC and narrowed inferiorly to reduce lung
and cardiac doses. Supraclavicular and axillary nodes were
covered by a single anterior field, or opposed anterior-
posterior fields as determined by the treating radiation
oncologist. The aim of the plans was to cover ≥ 95 % of
the CTVb ± supraclavicular/axillary nodes with ≥95 % of
the prescription dose. If CTVIMC was included, target
coverage of ≥80 % of the prescription dose to 100 % of the
volume was used.
Dosimetric evaluation
CTVb volumes, D95 coverage of the CTVb, and IMC
coverage (if treated) on FB and DIBH scans for each
patient were recorded. Heart V25, left lung V20, and mean
doses (Dmean) to the heart and LAD on FB and DIBH
scans were determined. Percent dose reduction conferred
by DIBH was calculated for mean heart and mean LAD
doses as well as left lung V20 for each patient.
Statistical analysis
Patients were classified into two treatment cohorts: pa-
tients who received whole breast radiotherapy alone ±
boost (WBRT), and patients who received breast or chest
wall radiotherapy plus regional nodal irradiation, including
the IMC and supraclavicular nodes (B/CWRT +RNI). Re-
sults were analyzed using R Software version 3.1.2 [22].
To evaluate FB vs. DIBH within each cohort, Wilcoxon
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signed-rank tests were used for continuous variables and
McNemar’s test was used to test differences for discrete
variables. The percent relative reduction when using DIBH
as opposed to FB was compared between the two cohorts
for mean heart dose, mean LAD dose, and lung V20 using
Wilcoxon rank-sum tests. The Bonferroni correction
method was used to correct for multiple comparisons. The
initial significance level of 0.05 was divided by the number
of tests to obtain a modified significance level.
Results
Demographics
Eleven patients received WBRT and nine patients received
B/CWRT + RNI. Table 1 shows the subjects’ baseline
demographics and radiotherapy treatment characteristics.
Stage distribution dictated the treatment technique and
therefore, was different between cohorts. Dose and frac-
tionation prescribed in this study represents standard
treatment prescriptions at our institution. The most com-
mon WBRT dose fraction was 42.5 Gy in 16 fractions. For
patients receiving additional RNI, dose fractionation ranged
from 40–50 Gy in 16–25 fractions to the breast or chest
wall and 37.5 Gy-45 Gy in 16–25 fractions to regional
nodes.
Dosimetric outcomes
Figure 1 shows a CT planning axial image through the
same portion of the left breast in FB (Fig. 1a) and DIBH
(Fig. 1b) in a patient with the IMC nodes included in the
80 % breast prescription isodose line. Comparison of aver-
age dose parameters to target volumes and OARs for FB
and DIBH are summarized in Table 2. The average D95
coverage of CTVb for the B/CWRT+RNI group in FB was
slightly lower (92.2 ± 8.1 %) than the planning dose con-
straint of D95 >95 %. However, after correcting for multiple
comparisons D95 of the CTVb was not significantly differ-
ent between FB and DIBH for both cohorts. Patients in the
B/CWRT+RNI group achieved comparable IMC coverage
with FB and DIBH planning (average V80 for CTVIMC
99.7 % and 98.9 % for FB and DIBH respectively, p = 1.000).
Mean CTVb volume was comparable for FB vs. DIBH in
both cohorts.
The DIBH technique significantly reduced Dmean Heart
compared to FB for both the WBRT (p = 0.001) and B/
CWRT + RNI (p = 0.004) groups. DIBH also significantly
reduced Dmean LAD in both treatment cohorts (p < 0.005
for both) when compared to FB. Heart V25 was not signifi-
cantly reduced with DIBH in either of the two cohorts
alone; while the combined group of all patients showed a
significant difference (p = 0.002). There was no significant
difference between FB and DIBH in left lung V20 for either
cohort alone or for all patients combined.
All patients in the WBRT group were able to meet a
Dmean Heart of <4 Gy on FB planning, but only five of nine
patients (56 %) in the B/CWRT+RNI group were able to
meet this constraint with FB. With DIBH, all patients in
both cohorts were able to meet the Dmean Heart <4 Gy
constraint.
Average relative percent reduction per patient in OAR
dose parameters with DIBH are presented in Table 3.
While Table 2 demonstrates that both groups of patients
benefit from DIBH, the data presented in Table 3 shows
that patients receiving regional nodal irradiation achieved a
statistically significantly greater percent reduction in Dmean
Heart and LAD from DIBH then those receiving WBRT
alone. The reduction in left lung V20 with DIBH was mod-
est (<10 %) and not significantly different between WBRT
and B/CWRT+RNI groups.
Discussion
There is a wealth of evidence from retrospective and plan-
ning studies demonstrating reduction in dose to the heart
and coronary arteries with DIBH treatment of left-sided
breast cancers. However, most published large retrospective
Table 1 Baseline demographic and radiotherapy treatment
parameters for left-sided breast cancer patients by treatment
cohort
Characteristics WBRT
(n = 11) (%)
B/CWRT + RNI
(n = 9) (%)
Median age (years), range 47 (39–54) 51 (34–69)
AJCC Stage
DCIS 3 (27) 0 (0)
I 5 (45) 0 (0)
II 3 (27) 5 (55)
III 0 (0) 4 (44)
ER/PR positive (for invasive disease) 7/8 (88) 7/9 (78)
HER 2+ (for invasive disease) 2/8 (25) 2/9 (22)
Surgery
Breast conserving 11 (100) 5 (56)
Mastectomy 0 (0) 4 (44)
RT boost to seroma 4 (36) 2 (22)
RT to internal mammary nodes 0 (0) 9 (100)
Breast/Chest wall RT dose
(Gy/# fraction)
40/16 0 (0) 2 (22)
42.5/16 10 (91) 4 (44)
45/25 0 (0) 1 (11)
50/25 1 (9) 2 (22)
Supraclavicular nodal RT dose
(Gy/# fraction)
37.5/16 N/A 6 (67)
45/25 N/A 3 (33)
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studies have combined all patients, irrespective of regional
nodal irradiation in their analysis [8]. Similarly, few pub-
lished planning studies have compared dosimetric out-
comes between patients receiving WBRT alone (without
IMC treatment) and those requiring additional regional
nodal irradiation including treatment of the IMC nodes
[7–14]. A planning study from Toronto demonstrated that
DIBH reduced heart dose for some patients treated with
wide breast tangents but included only five patients [15].
The current study is one of the larger studies evaluating
differences in OAR dose reductions with DIBH comparing
WBRT alone to patients receiving breast/chest wall plus
regional nodal irradiation employing a modified wide tan-
gents technique to include the IMC nodes.
In this study, the average CTVb volumes and D95 cover-
age with DIBH were comparable to FB within each cohort,
confirming minimal bias in regards to volume delineation
and planning. The study results are similar to published
retrospective and planning studies demonstrating that
DIBH lowered Dmean Heart and LAD doses [7–15]. Plan-
ning studies have shown variable results regarding the im-
pact of DIBH on ipsilateral lung dose-volume relationships.
Some authors have reported that DIBH significantly re-
duced lung dose while others showed no difference [9–13].
In the current study, DIBH did not significantly reduce left
lung V20. It is possible that the small sample sizes used in
this study, however, did not achieve the statistical power to
show this effect. Further studies with larger sample sizes
are required to determine if there is a statistical difference
in lung V20 between FB and DIBH.
DIBH significantly reduced both Dmean Heart and LAD
doses in both treatment cohorts. A literature review of clin-
ical and dose volume predictors for radiation-induced heart
disease found no consensus regarding a safe threshold dose
for the heart or LAD [22]. However, the ongoing NSABP-
B-51/RTOG1104 study protocol has recommended a Dmean
Heart constraint for left sided breast/chest wall irradiation
of <4 Gy [16]. Although there is evidence to suggest no safe
threshold dose to the heart, the proposed dose of <4 Gy
served as a reference to enable comparison in the current
study [4,23]. All patients in the WBRT group were able to
meet a Dmean Heart <4Gy with FB while only slightly over
half of the patients receiving regional nodal irradiation were
able to meet this constraint with FB. All patients were able
to meet this constraint with DIBH, suggesting that DIBH
provides a greater benefit for patients receiving regional
nodal irradiation when using a modified wide tangent tech-
nique. Similarly, the relative percent reduction in Dmean
Heart and LAD dose with DIBH was significantly greater in
the B/CWRT+RNI group compared to the WBRT group.
To improve treatment planning efficiency, these observa-
tions have led to an institutional policy to use DIBH in all
patients with left-sided breast cancer when the RT intent is
to include the regional lymph nodes, but to use it selectively
if the RT intent is whole breast RT alone.
In this study a modified wide tangent technique was used
for IMC nodal irradiation. Results from some treatment
planning studies have suggested that partially-wide tangent
techniques may provide superior dosimetric coverage of
the IMC nodes compared to photon-electron techniques
[24, 25]. The disadvantage of using modified wide tangents
for IMC node irradiation is the potentially increased dose
to the heart and lung; however we have shown here that
DIBH significantly reduces this effect. The relative effect-
iveness of DIBH for patients receiving alternate forms of
regional nodal irradiation, such as the photon-electron
technique, is not examined in this study.
A limitation of the current study is the relatively small
sample size. However, the patients were consecutive
eligible cases, so the findings may more readily translate
to other populations. Furthermore, all patients treated to
the regional lymph nodes also had the IMC nodes in-
cluded. Whether DIBH would be needed as frequently if
the IMC nodes were excluded could not be addressed by
the current data. However, the report of the EORTC study
showing a survival advantage for the use of IMC plus
medial supraclavicular RT may increase the frequency of
IMC treatment [26]. Both Dmean Heart and Dmean LAD
Fig. 1 CT simulation axial images of one patient at (a) FB and (b)
DIBH with treatment plan isodose lines. The IMC nodes contour is
shown in green
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were significantly reduced in both groups. One may argue
that the LAD is a more important target to avoid in the
pathogenesis of long term cardiac complications [14, 27].
Further studies are required to determine threshold doses
to cardiac structures in breast radiotherapy.
Conclusions
DIBH provided greater percent reductions in mean heart
and LAD doses for patients receiving regional nodal
irradiation that included the IMC nodes using a modified
wide tangent technique than for whole breast RT alone. All
patients receiving WBRT alone met the mean heart dose
constraint of <4 Gy on free breathing planning, while only
slightly over half of patients receiving regional nodal irradi-
ation were able to meet this constraint in free breathing.
Table 2 Comparison of average dose parameters for targets and OARs for left-sided breast cancers by treatment cohort
Parameter WBRT WBRT FB vs. DIBH
p-value*
B/CWRT + RNI B/CWRT FB vs. DIBH
p-value***
All Patients FB vs. DIBH
p-value*
CTVb Volume (cc)
FB 515.5 ± 356.9 0.577 489.2 ± 200.8 0.496 503.7 ± 290.2 0.349
DIBH 511.8 ± 354.6 491.3 ± 218.6 502.6 ± 294.0
D95 for CTVb (%)
FB 97.3 ± 1.4 0.286 92.2 ± 8.1 0.030 95.0 ± 5.9 0.013
DIBH 97.7 ± 1.3 96.2 ± 3.0 97.0 ± 2.3
V80 IMC (%)
FB N/A N/A 99.7 ± 0.9 1.000 N/A N/A
DIBH N/A 98.9 ± 3.3 N/A
Dmean Heart (cGy)
FB 166.1 ± 71.0 0.001** 375.7 ± 186.0 0.004** 260.5 ± 169.3 <0.001**
DIBH 110.8 ± 32.1 145.0 ± 37.7 126.2 ± 38.0
V25 Heart (%)
FB 0.8 ± 1.4 0.059 4.0 ± 3.4 0.014 2.2 ± 2.9 0.002**
DIBH 0.1 ± 0.4 0.0 ± 0.1 0.1 ± 0.3
Dmean LAD (cGy)
FB 1004.6 ± 892.4 0.002** 1802.8 ± 917.8 0.004** 1363.8 ± 969.4 <0.001**
DIBH 420.0 ± 277.4 396.2 ± 81.5 409.3 ± 208.4
V20 Left Lung (%)
FB 10.5 ± 4.6 0.067 18.3 ± 5.1 0.250 14.0 ± 6.2 0.029
DIBH 8.5 ± 3.6 16.3 ± 2.8 12.0 ± 5.1
Patients meeting
Dmean < 4Gy (fraction, %)
FB 11/11 (100) N/A 5/9 (56) 0.134 16/20 (80) 0.134
DIBH 11/11 (100) 9/9 (100) 20/20 (100)
Wilcoxon signed-rank test is used for comparison of all continuous variables, and McNemar's test is applied for discrete variables
Significant p-values after adjusting for multiple testing are indicated by a double asterisk (**)
Abbreviations: WBRT = whole breast RT ± boost cohort, B/CWRT + RNI = breast or chest wall + regional nodal RT cohort, FB = free-breathing, DIBH = deep
inspiration breath hold, CTVb = CTV for breast or chest wall, IMC = internal mammary chain nodes, D95 = Dose to 95 % target volume,V80 = % volume of organ
receiving 80 % of the prescription dose, V25 = % volume of organ receiving 25 Gy, Dmean = Mean dose, LAD = left anterior descending coronary artery, V20 = %
volume of organ receiving 20 Gy, N/A = not applicable. Data shown are mean values with one standard deviation. *In this group, to achieve significance p-values
must be < 0.0083 to account for multiple testing. ***In this group, to achieve significance p-values must be < 0.0071 to account for multiple testing. **Indicates
significance when compared to the Bonferroni adjusted criterion
Table 3 Average patient percent relative reduction in dose
parameters with DIBH compared to FB for left-sided breast
cancer patients by treatment cohort. Significant p-values after
adjusting for multiple testing are indicated by a double asterisk
(**)
Parameter WBRT B/CWRT + RNI p-value*
Dmean Heart 29.2 % 55.9 % 0.003**
Dmean LAD 43.5 % 72.1 % 0.014**
V20 Left Lung 8.9 % 6.6 % 0.305
Wilcoxon sum-rank test used in for comparison of all variables
*In this group, to achieve significance p-values must be < 0.0167 to account
for multiple testing. **Indicates significance when compared to the Bonferroni
adjusted criterion
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DIBH is justified for all patients receiving RT for left-sided
breast cancer, but as a minimum, should be used regularly
for all left-sided breast cancer patients receiving breast/
chest wall RT plus nodal RT.
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